GLP-1 acts on those receptors in the brain and it results in the patients having decreased appetite and decreased hunger," explains Dr Sukhvinder Singh Saggu, Director Minimal Access, GI & Bariatric Surgery at the CK Birla Hospital, Delhi
In many cases, the metabolic benefits of these medications may outweigh theoretical concerns, particularly for patients with significant obesity or poorly controlled diabetes, which themselves carry health risks
most continuous Mounjaro users for diabetes reach it within 23 months and pay $0 thereafter
20, 2025, my team published a study of more than 2.4 million people that evaluated the risks and benefits of GLP-1 drugs across 175 possible health outcomes
[Google Scholar] Herz A (1997) Endogenous opioid systems and alcohol addiction